Clinical Immunology · Autosomal Dominant Agammaglobulinemia Type 10

Living with AGM10: Infection Prevention and Daily Management

At a Glance

People living with AGM10 need lifelong immunoglobulin replacement and an individualized plan to prevent and quickly treat infections. Regular immunology follow-up, lung monitoring, vaccine guidance, and a written sick-day plan help reduce complications such as bronchiectasis.

Living with Agammaglobulinemia Type 10 (AGM10) is a marathon, not a sprint. Because this condition means your body cannot produce its own antibodies, your health depends on a consistent partnership with a clinical immunology team. While the diagnosis is rare, the framework for staying healthy focuses on three pillars: constant protection, proactive monitoring, and aggressive response to new symptoms ^[1]^[2].

A Framework for Long-Term Monitoring

Because AGM10 was only recently discovered, there is no single “universal” schedule for testing. Instead, your immunologist will create a personalized surveillance plan. A common clinical framework includes:

Quarterly or Semi-Annual Reviews: Many immunology clinics see patients every 3 to 6 months to review infection history, antibiotic use, and overall energy levels ^[3].
Trough IgG Testing: Your “trough” is the lowest level of IgG in your blood, measured just before your next infusion. This number is used to adjust your dose. However, doctors now emphasize that your clinical health—how many infections you are actually getting—is more important than any single lab number ^[4]^[5].
Lymphocyte Subsets: Periodic checks of your immune cell counts (B cells, T cells, NK cells, and dendritic cells) help ensure no other parts of your immune system are changing over time ^[6].

Protecting Your Lungs

The most significant long-term risk in agammaglobulinemia is bronchiectasis—a condition where the airways in the lungs become permanently scarred and widened due to repeated infections ^[7]^[8].

Proactive Screening: Even if you feel well, structural lung damage can accumulate silently. Specialists recommend baseline and periodic Pulmonary Function Tests (PFTs), such as spirometry, to measure how well your lungs are working ^[8]^[9].
Imaging: If you have a chronic cough, frequent pneumonia, or declining lung function, your doctor may order a High-Resolution CT (HRCT) scan. It is not used for routine screening due to radiation, but is ordered when symptoms, abnormal testing, or clinical concern for bronchiectasis justifies it ^[10]^[8].
Aggressive Response: The best way to prevent lung damage is prompt clinician contact for defined symptoms. Follow an explicit rescue plan with specialist-directed use of cultures or airway clearance, rather than treating every respiratory symptom with antibiotics yourself ^[11]^[12].

The Truth About Vaccines

Vaccination is a complex topic for people with AGM10. Because you lack B cells, your body cannot create the “memory” antibodies that most vaccines rely on ^[13].

Live Vaccines: Generally, live-attenuated vaccines (such as the oral polio vaccine or MMR) are contraindicated. Because your immune system is weakened, these live but weakened viruses could potentially cause a serious infection ^[13]^[14].
Inactivated and mRNA Vaccines: Vaccines like the annual flu shot or mRNA COVID-19 vaccines are considered safe because they do not contain live virus. While they may not provide the same level of protection as they do for others, research shows that some patients can still develop a T-cell response, which may provide a backup layer of defense against severe disease ^[15]^[16].
The IgRT “Bonus”: It is important to know that the immunoglobulin (IgRT) you receive is made from thousands of donors. This means it naturally contains antibodies against many common viruses, including COVID-19 and influenza ^[17]^[18]. However, this varies by product and batch, and does not reliably prevent infection; it is not a substitute for vaccination, exposure precautions, or prompt treatment.

Quality of Life and Mental Health

Living with a chronic, ultra-rare condition can bring a unique form of “medical anxiety.” The need for lifelong infusions and the constant threat of infection are significant burdens ^[19].

Fatigue: Many patients report a “wear-off” effect where they feel more fatigued in the days leading up to their next infusion ^[20].
Daily Prevention: Expand prevention beyond hand hygiene to include dental care, food and water precautions, travel planning with an emergency letter, and a written fever plan with after-hours contact info.
Community: Connecting with others who have similar B-cell deficiencies (like XLA) can be incredibly helpful, even if they don’t have the exact same AGM10 mutation. You are not alone in this journey.

Common questions in this guide

Which vaccines are usually recommended for someone with AGM10?

Inactivated vaccines, such as the flu shot, and mRNA COVID-19 vaccines are generally considered safe, although they may not produce the same antibody protection in AGM10. Some people may still develop protection from T cells, another part of the immune system, so an immunologist should recommend the vaccines and timing for your situation.

Are live vaccines safe for people with AGM10?

Live-attenuated vaccines, including the oral polio vaccine and MMR, are generally contraindicated in people with AGM10. Because the immune system cannot make normal antibody protection, a live vaccine could potentially cause a serious infection. Ask your immunologist before receiving any vaccine.

How often should lung function be checked with AGM10?

People with AGM10 may need baseline and periodic pulmonary function tests, such as spirometry, to look for lung problems that can develop silently. The schedule should be individualized by the clinical team. A high-resolution CT scan is usually reserved for symptoms, abnormal testing, or concern about bronchiectasis rather than routine screening.

How is immunoglobulin replacement monitored in AGM10?

Immunoglobulin replacement therapy supplies antibodies that the body cannot make. A trough IgG test may be taken just before an infusion to help adjust the dose, but the number of infections and your overall health are more important than one lab result. Immunology visits commonly occur every three to six months, with timing based on individual needs.

What daily steps can help prevent infections with AGM10?

Use careful hand hygiene, dental care, food and water precautions, and a written fever or sick-day plan with after-hours contact information. Travel planning should include an emergency letter explaining AGM10 and immunoglobulin treatment. Do not treat every respiratory symptom with antibiotics on your own; follow the rescue plan from your specialist.

What should I do if I develop a cough, fever, or other new symptoms?

Contact your immunology team promptly for a persistent cough, fever, pneumonia symptoms, or other new or worsening respiratory problems. Your specialist may recommend cultures, airway clearance, or prescribed antibiotics depending on the situation. Keep your written fever and emergency plan accessible so you know whom to call after hours.

Get notified when new evidence is published on agammaglobulinemia 10, autosomal dominant.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Key takeaways

Regular immunology visits may review infection history, antibiotic use, energy levels, trough IgG, and immune-cell counts, with the schedule tailored to each patient.
Clinical health and infection frequency are more important than a single trough IgG result when clinicians assess immunoglobulin replacement.
Baseline and periodic pulmonary function tests can monitor for silent lung damage, while high-resolution CT is generally reserved for symptoms or abnormal findings.
Live-attenuated vaccines are generally contraindicated, while inactivated and mRNA vaccines are usually considered safe but should be discussed with an immunologist.
Hand hygiene, dental care, food and water precautions, travel documentation, and a written fever plan support daily infection prevention and prompt treatment.

References (20)

1
X-linked agammaglobulinemia: ınvestigation of clinical and laboratory findings, novel gene mutations and prevention of ınfective complications in long-term follow-up.
Yıldırım İ, Topyıldız E, Bilgin RBG, et al.
American journal of clinical and experimental immunology 2021; (10(1)):37-43.
PMID: 33815962
2
Pulmonary Manifestations of Inborn Errors of Immunity: Diagnostic and Therapeutic Insights.
Napiorkowska-Baran K, Cofta S, Treichel P, et al.
Life (Basel, Switzerland) 2025; (15(12)) doi:10.3390/life15121838.
PMID: 41465777
3
Reconstitution of IgG Subclasses Following Immunoglobulin Administration in Adult Patients with Common Variable Immune Deficiency.
Reeder D, Gupta S
International archives of allergy and immunology 2021; (182(3)):243-253 doi:10.1159/000510790.
PMID: 33053553
4
Immunoglobulin G Trough Levels and Infection Risk in Adults with Inborn Errors of Immunity Receiving Immunoglobulin Therapy.
Aktaş ÖÖ, Özer NO, Kaplankıran C, et al.
Medicina (Kaunas, Lithuania) 2025; (61(9)) doi:10.3390/medicina61091549.
PMID: 41010940
5
Serial Serum Immunoglobulin G (IgG) Trough Levels in Patients with X-linked Agammaglobulinemia on Replacement Therapy with Intravenous Immunoglobulin: Its Correlation with Infections in Indian Children.
Suri D, Bhattad S, Sharma A, et al.
Journal of clinical immunology 2017; (37(3)):311-318 doi:10.1007/s10875-017-0379-5.
PMID: 28321612
6
Predominantly Antibody-Deficient Patients With Non-infectious Complications Have Reduced Naive B, Treg, Th17, and Tfh17 Cells.
Edwards ESJ, Bosco JJ, Aui PM, et al.
Frontiers in immunology 2019; (10()):2593 doi:10.3389/fimmu.2019.02593.
PMID: 31803177
7
Long-term follow-up of 168 patients with X-linked agammaglobulinemia reveals increased morbidity and mortality.
Lougaris V, Soresina A, Baronio M, et al.
The Journal of allergy and clinical immunology 2020; (146(2)):429-437 doi:10.1016/j.jaci.2020.03.001.
PMID: 32169379
8
Evaluation of pulmonary findings in patients with humoral immunodeficiency.
Karalı Z, Karalı Y, Çekiç Ş, et al.
Turk pediatri arsivi 2020; (55(2)):174-183 doi:10.14744/TurkPediatriArs.2020.46656.
PMID: 32684763
9
Respiratory Health and Related Quality of Life in Patients with Congenital Agammaglobulinemia in the Northern Region of the UK.
Bryan BA, Battersby A, Shillitoe BM, et al.
Journal of clinical immunology 2016; (36(5)):472-9 doi:10.1007/s10875-016-0284-3.
PMID: 27091141
10
Lung magnetic resonance imaging with diffusion weighted imaging provides regional structural as well as functional information without radiation exposure in primary antibody deficiencies.
Milito C, Pulvirenti F, Serra G, et al.
Journal of clinical immunology 2015; (35(5)):491-500 doi:10.1007/s10875-015-0172-2.
PMID: 26067227
11
Secondary antibody deficiencies.
Dhalla F, Misbah SA
Current opinion in allergy and clinical immunology 2015; (15(6)):505-13 doi:10.1097/ACI.0000000000000215.
PMID: 26406183
12
Respiratory infectious burden in a cohort of antibody deficiency patients treated with immunoglobulin replacement therapy: The impact of lung pathology and gastroesophageal reflux disease.
Cutajar J, Gkrania-Klotsas E, Sander C, et al.
The journal of allergy and clinical immunology. Global 2023; (2(4)):100133 doi:10.1016/j.jacig.2023.100133.
PMID: 37781665
13
Vaccination in PADs.
Milito C, Soccodato V, Collalti G, et al.
Vaccines 2021; (9(6)) doi:10.3390/vaccines9060626.
PMID: 34207916
14
[Sepsis due to Pseudomona as a debut of a primary immunodeficiency in a child].
Vera Sáez-Benito MC, López Úbeda M, Madurga Revilla P, et al.
Archivos argentinos de pediatria 2016; (114(6)):e444-e447 doi:10.5546/aap.2016.e444.
PMID: 27869430
15
Response to mRNA COVID-19 vaccination in three XLA patients.
Squire JD, Joshi AY
Vaccine 2022; (40(36)):5299-5301 doi:10.1016/j.vaccine.2022.07.046.
PMID: 35934578
16
Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity.
van Leeuwen LPM, GeurtsvanKessel CH, Ellerbroek PM, et al.
The Journal of allergy and clinical immunology 2022; (149(6)):1949-1957 doi:10.1016/j.jaci.2022.04.002.
PMID: 35421449
17
SARS-CoV-2 spike antibody concentration in gamma globulin products from high-prevalence COVID-19 countries are transmitted to X-linked agammaglobulinemia patients.
Raphael A, Shamriz O, Tvito A, et al.
Frontiers in immunology 2023; (14()):1156823 doi:10.3389/fimmu.2023.1156823.
PMID: 37063907
18
Reactogenicity and immunogenicity of the second COVID-19 vaccination in patients with inborn errors of immunity or mannan-binding lectin deficiency.
Göschl L, Mrak D, Grabmeier-Pfistershammer K, et al.
Frontiers in immunology 2022; (13()):974987 doi:10.3389/fimmu.2022.974987.
PMID: 36189225
19
Quality of life of X-linked agammaglobulinemia patients in the United Kingdom.
Shillitoe B, Bourne H, Stroud C, et al.
Journal of human immunity 2026; (2(3)):e20250198 doi:10.70962/jhi.20250198.
PMID: 42169998
20
Clinical and laboratory observation on immunoglobulin replacement therapy switching from an intravenous to a subcutaneous route in a Malaysian X-linked agammaglobulinemia patient.
Adli A, Wahab AA, Abdul Latiff AH, et al.
The Medical journal of Malaysia 2022; (77(1)):95-97.
PMID: 35087003

This page provides general information about living with AGM10, infection prevention, vaccines, and monitoring for education only; it does not replace medical advice. Follow an individualized plan from your immunologist, especially for vaccines, infusions, and respiratory symptoms.